Navigation Links
Investigational Diabetes Drug May Also Have Future As Treatment for Parkinson's Disease
Date:9/19/2013

KALAMAZOO, Mich., Sept. 19, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the presentation of new data showing an investigational drug being studied to treat diabetes, MSDC-0160, had a protective effect  on nerve cells in the brain that control movement, balance and walking.  These results in laboratory and animal models of Parkinson's disease suggest MSDC-0160 may have the potential to modify the course of Parkinson's disease. The Company is preparing for the start of clinical trials, which could begin in late 2014.

These results were generated in collaboration with Patrik Brundin, MD, PhD, Head of the Laboratory of Translational Parkinson's Disease Research and Director of the Center for Neurodegenerative Science at the Van Andel Institute (VAI). The data were presented by post-doctoral fellow Anamitra Ghosh at the "Grand Challenges in Parkinson's Disease" symposium, which is being convened September 18 – 19 at VAI (Grand Rapids, MI).

First in Class
MSDC-0160 is the first in a new class of insulin sensitizers called mTOT Modulators™, which appear to exert their therapeutic effects through a new drug target located in the inner mitochondrial membrane. MSDC-0160 has been shown to be well-tolerated and no significant safety issues were noted in studies in patients with type 2 diabetes or elderly patients with dementia due to Alzheimer's disease. In a Phase 2b clinical trial in 258 patients with type 2 diabetes, MSDC-0160 was shown to lower hemoglobin A1c significantly without the side effect profile of currently marketed insulin sensitizers, which are PPARg agonists. In a recently completed Phase 2a trial in 29 patients with dementia due to Alzheimer's disease (NCT01374438), MSDC-0160 was shown to maintain or increase glucose metabolism in the brain, as measured by FDG-PET imaging, in predefined regions of interest in the brain associated with cognitive decline.

Mitochondria and Parkinson's Disease
Parkinson's disease is a chronic, degenerative neurological disorder that affects an estimated one million people in the United States, and more than five million worldwide. Impaired mitochondrial function has been implicated in the development of Parkinson's disease. Mitochondria are the "power plants" of the cell, generating energy needed for cell activity. Therapies that improve mitochondrial function may have the potential to slow the progression of the disease.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. This is accomplished through the work of over 200 researchers in more than 20 on-site laboratories and in collaborative partnerships that span the globe. Find out more about Van Andel Institute or donate by visiting www.vai.org

About Patrik Brundin, MD, PhD
Patrik Brundin, M.D., Ph.D. Brundin has more than 30 years of experience with neurodegenerative diseases, Parkinson's disease pathogenesis, and therapeutic neural grafting into people with Parkinson's disease. He is one of the top cited researchers in the field of neuroscience with around 300 publications on Parkinson's disease and related topics. In addition to managing laboratories at VAI and at Lund University, Sweden, he is the co-editor in chief of the Journal of Parkinson's Disease and has coordinated multiple international research programs.  


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
2. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
3. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
4. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
5. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
8. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
9. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
10. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
11. Research Report on Chinas Diabetes Drug Market, 2013-2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
(Date:3/24/2017)... March 24, 2017   Sienna Biopharmaceuticals, Inc. , ... today announced that Richard Peterson will join ... Peterson, who brings more than two decades ... , who is retiring at the end of April ... capacity. Peterson joins Sienna from Novan, Inc., where he ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Global Markets" report to their offering. ... The Global Market ... Billion in 2016 at a CAGR of 8.9%, ... and non-energetic bioproducts into seven major product segments: bio-derived chemicals, ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScanĀ® technology provides the fastest and most ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
Breaking Biology News(10 mins):